Anti-oxidant treatment for shock: vitamin E but not vitamin C improves survival.

Abstract

Anti-oxidant therapy has been effective for treatment of experimental shock. In this study, the efficacy of Trolox (Aldrich Chemical Co., Milwaukee, WI), a water-soluble vitamin E analogue, and ascorbic acid (vitamin C) was evaluated in a rat model of hemorrhagic shock and resuscitation. In two prospective trials, rats were phlebotomized (27 mL/kg) and left in shock for 45 minutes. Resuscitation was then instituted by continuous IV infusion with lactated Ringer's (LR) (54 mL/kg) over 60 min. In Trial 1, rats were randomized to receive either placebo (LR) or Trolox (50 mg/kg) in LR. In Trial 2, rats were randomized to LR alone or ascorbic acid (50 mg/kg) in LR. Survival for ascorbic acid-treated rats (35 per cent) was not different than for control rats (35 per cent). However, the addition of Trolox to infusion significantly improved 72 hour survival, 75 per cent versus 40 per cent respectively, for Trolox-treated and control animals. These data demonstrate that Trolox is of survival benefit when added to resuscitation in this model. This benefit does not appear to be related to blood pressure or white cell adhesion. Trolox is more effective than ascorbic acid in this model.

• Authors: K Daughters, K Waxman, A Gassel, S Zommer
• Journal: The American surgeon (Am Surg) Vol. 62 Issue 10 Pg. 789-92 (Oct 1996) ISSN: 0003-1348 [Print] United States
• PMID: 8813156 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Antioxidants
• Chromans
• Vitamin E
• Ascorbic Acid
• 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid

Topics

• Animals
• Antioxidants (therapeutic use)
• Ascorbic Acid (therapeutic use)
• Blood Pressure (drug effects)
• Chromans (therapeutic use)
• Disease Models, Animal
• Fluid Therapy (methods)
• Leukocyte Adherence Inhibition Test
• Leukocytes (drug effects, immunology)
• Prospective Studies
• Rats
• Rats, Sprague-Dawley
• Resuscitation
• Shock, Hemorrhagic (drug therapy)
• Vitamin E (analogs & derivatives, therapeutic use)